Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, ...

Hoppus recounts the band’s rise to fame, being diagnosed with an aggressive form of blood cancer during COVID-19, and some 30 ...

It is an aggressive disease that progresses rapidly ... "People with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options, especially those who are not candidates ...

and primary mediastinal large B-cell lymphoma (PMBCL) who have received two or more systemic therapies. Both DLBCL and PMBCL are aggressive forms of non-Hodgkin lymphoma. In the UK, around 14,200 ...

Facebook post from Sara Wald Coven of Lyndhurst summed it up best: “Bragging rights! My brother makes the world better.” ...

It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...